Clinical Genomics Pty Ltd. develops and delivers healthcare products for early detection and prevention of disease. The company is headquartered in North Ryde, Australia.

Commonwealth Scientific & Industrial Research Organisation provides scientific and industrial research services. It plays a role in collaboration within the Australian national innovation system and as an advisor to government, industry and the community. The company was founded in 1916 and is headquartered in Canberra, Australia.

Applied Proteomics is a platform for discovering protein biomarkers that advances proteomics. It offers the application of proteomics in diagnostics and personalized medicine to improve healthcare outcomes. It develops a proteomics platform solution to make protein-based biomarker discovery possible as a replicable, industrial application ready to be applied to health diagnostic problems.

Ventana Medical Systems, Inc., is a world leader and innovator of tissue-based diagnostic solutions for patients worldwide. The company passionately pursues its mission to improve the lives of all patients afflicted with cancer. Ventana Medical Systems discover, develop, and deliver medical diagnostic systems and biopsy based cancer tests that are shaping the future of healthcare. As the leading supplier of cancer diagnostic systems to the pathology market, Ventana manufactures over 220 cancer tests with related instruments right here in southern Arizona for 80 countries, and most importantly, for 4 million people afflicted with cancer yearly around the world. Ventana products provide healthcare professionals with a total solution for all critical steps involved in the analysis of tissue biopsies. This pioneering company also offers premier workflow solutions to improve laboratory efficiency and preserve patient safety. Ventana is committed to accelerating the discovery and development of new cancer tests that allow pathologists to analyze patient samples at the molecular level to help determine the best course of therapy for each individual patient. Ventana enables this with its global leadership as the number one Pharma Industry Partner of Choice in the development and commercialization of companion diagnostics for cancer patients. Ventana Medical Systems is a member of the Roche Group that is drawing on powerful partnerships with world-class scientific institutions.

Hospital Clínic de Barcelona is a Spanish private company located in Barcelona. The firm operates hospital. Josep Maria Campistol is currently the CEO of the company.\nThe company says this about itself: Hospital Clínic of Barcelona is a public university hospital with a centuries-long history. With 4500 employees, it is one of the leading healthcare centers in Spain and the first in scientific production. The hospital offers quality care, high-level excellence, and competitive biomedical research and a strong teaching commitment to train professionals. All of this is included in an excellent balanced management with the aim of offering society a humanized, cutting-edge medicine.

Oncotherapy science (OTS) is“ to deliver cancer therapeutics and treatments with higher efficacy and fewer side effects to patients suffering from cancer as soon as possible, and to overcome the fight against cancer. Was established with the aim of OTS brought Professor Genomix (Science that handles genetic information systematically) as a pioneer in the medical field with Prof. Atsushi Nakamura (Director, Cancer Precision Medical Research Center, Institute of Cancer, Professor Emeritus, The University of Tokyo, Professor Emeritus of Chicago University) Joint research to identify target molecules suitable for cancer drug development based on comprehensive gene expression analysis, and promote research and development of small molecule drugs, cancer peptide vaccines and antibody drugs for those targets.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Exact Sciences is a molecular diagnostics company focused on colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA (sDNA) technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.

Bayer HealthCare Ltd., established on 1995-08-25, Business scope includes licensed projects:pharmaceutical production;Pharmaceutical commissioned production;Drug Wholesale;Drug import and export;Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business;food sales;Health food production;food production;Production of formula food for special medical purpose;Cosmetic production;Production of hygiene products and single-use medical products;Disinfectant production(Free of Hazardous Chemicals).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Medical Research and Experimental Development;Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Cosmetics Wholesale;Cosmetics Retail;internet sales(Except for products that require a license for sale);Food import and export;software development;software sales;Retailing of computer software, hardware and auxiliary equipment;Wholesale of computer software, hardware and auxiliary equipment;Manufacturing of computer software, hardware and peripheral equipment;Software outsourcing service;Information Consulting Service(Not including licensing information consulting services);Information Technology Consulting Services;Special Equipment Repair;Import and export;Technology Import and Export;Import and export agency;Sales of hygiene products and single-use medical products;Disinfectant sales(Free of Hazardous Chemicals);Manufacturing of daily chemical products;Sales of daily chemical products.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)(Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Universiteit Utrecht Holding BV provides portfolio management and commercial development services. It strengthen and broaden cooperation among partners encompassing companies, governmental institutions, cultural and social organizations. The company was founded in 1996 and is headquartered in Utrecht, the Netherlands.

anghai Ruiyi Biotechnology Co., Ltd. was established in Shanghai in 2014 and is a national high-tech enterprise. At present, it has established branches in Hangzhou, Qingdao and Guiyang. It is a professional genetic technology and health service company. The company has always been adhering to the corporate philosophy of "forge ahead" and is committed to providing customers with the highest quality products and services. Since its inception, Shanghai Ruiyi Biotechnology Co., Ltd. has quickly established cooperation with many well-known research institutes at home and abroad, and has attracted many elites from the fields of genomics, medicine and bioinformatics. Up to now, the company has obtained more than 40 software copyrights and a number of patents.

Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts is a teaching hospital of Harvard Medical School. It was formed out of the 1996 merger of Beth Israel Hospital (founded in 1916) and New England Deaconess Hospital (founded in 1896). Among independent teaching hospitals, Beth Israel Deaconess Medical Center consistently ranks in the top three recipients of biomedical research funding from the National Institutes of Health. Research funding totals nearly $200 million annually. BIDMC researchers run more than 850 active sponsored projects and 200 clinical trials. The Harvard-Thorndike General Clinical Research Center, the oldest clinical research laboratory in the United States, has been located on this site since 1973.

Shanghai Kunyuan Health Technology Co., Ltd., established on 2018-05-29, Business scope includes engaging in health technology,gene technology,Biological Technology,medical technology,Technical consulting in the field of information technology,Technical Services,technology development,technology transfer,Chemical raw materials and products(Removal of hazardous chemicals,Monitor Chemicals,civilian explosives,precursor chemicals),Research and development of pharmaceutical intermediates,Sales,Health Management Consulting,e-commerce(Not to engage in financial business),Expo Services,food sales,Engaged in the import and export of goods and technology. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Kiadis Pharma BV operates as a is a clinical stage biopharmaceutical company focused on research, development and future commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Its products include: ATIR101 and ATIR201. The firm’s products are based on hematopoietic blood-forming stem cell transplants from donors. The company was founded in 1997 and is headquartered in Amsterdam, the Netherlands.

Universal Diagnostics S.L. (UDX) is a Spanish in-vitro diagnostics company developing a platform of minimally-invasive, blood-based solutions for detecting cancer early when treatment options are more plentiful and survival rates are still high. UDX believes that the best way to fight against cancer is by detecting it early. The UDX diagnostic platform is designed to detect various cancer types, e.g. colorectal, liver, pancreatic, lung, and gastric cancer via one simple blood test. The assays rely on a curated set of proprietary methylation marker panels; a simple blood sample collected as part of a routine check-up, can be processed at a reference laboratory or hospital using standard equipment and then uploaded to the UDX Cloud for final algorithmic analysis. UDX’s first marker panel is a colorectal cancer screening test. The test identifies individuals who need to be referred for colonoscopy. Colorectal cancer is the 3rd most frequent cancer and 2nd deadliest cancer worldwide. The challenge is that colorectal cancer is mostly detected in late stages, with significantly decreased survival rates (11% survival rate in stage IV vs. 85% survival rate in stage I). To develop the test and execute its R&D and operations, UDX partners with international research institutions, hospitals, universities, and biobanks around the globe.

Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.